CN115304600B - mTOR inhibitor, preparation method and application - Google Patents
mTOR inhibitor, preparation method and application Download PDFInfo
- Publication number
- CN115304600B CN115304600B CN202211194474.5A CN202211194474A CN115304600B CN 115304600 B CN115304600 B CN 115304600B CN 202211194474 A CN202211194474 A CN 202211194474A CN 115304600 B CN115304600 B CN 115304600B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- reaction solvent
- acid
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940124302 mTOR inhibitor Drugs 0.000 title claims abstract description 13
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 126
- 201000011510 cancer Diseases 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 6
- 208000036142 Viral infection Diseases 0.000 claims abstract description 6
- 208000026278 immune system disease Diseases 0.000 claims abstract description 6
- 230000009385 viral infection Effects 0.000 claims abstract description 6
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 116
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 75
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 40
- 239000007810 chemical reaction solvent Substances 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 26
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000036210 malignancy Effects 0.000 claims description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- 239000003513 alkali Substances 0.000 claims description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 14
- 239000003638 chemical reducing agent Substances 0.000 claims description 11
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims description 10
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 claims description 6
- -1 hexafluorophosphate Chemical compound 0.000 claims description 6
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- PSEHHVRCDVOTID-NAVXHOJHSA-N chloro-bis[(1s,3s,4r,5s)-4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]borane Chemical compound C([C@@H]([C@H]1C)B(Cl)[C@@H]2[C@@H](C)[C@@]3(C[C@](C2)(C3(C)C)[H])[H])[C@]2([H])C(C)(C)[C@@]1([H])C2 PSEHHVRCDVOTID-NAVXHOJHSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract description 13
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 230000019491 signal transduction Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 230000004064 dysfunction Effects 0.000 abstract description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000007787 solid Substances 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 19
- 238000003756 stirring Methods 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 15
- 238000012544 monitoring process Methods 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 230000001276 controlling effect Effects 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 6
- 238000007086 side reaction Methods 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 4
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 101000678286 Danio rerio Eukaryotic translation initiation factor 4E-binding protein 3-like Proteins 0.000 description 1
- 101000800913 Dictyostelium discoideum Eukaryotic translation initiation factor 4E-1A-binding protein homolog Proteins 0.000 description 1
- 101000800906 Drosophila melanogaster Eukaryotic translation initiation factor 4E-binding protein Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000005789 organism growth Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an mTOR inhibitor, a preparation method and application, and belongs to the technical field of chemical drugs. A compound having a structure shown in formula I or pharmaceutically acceptable salts thereof:
in the formula, R 1 Is selected from
、
、
、
；R 2 Is selected from C 1 ‑C 6 Alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
、
、
、
、
、
；R 3 Selected from H, OH, OCH 3 、OCH 2 CH 3 、OCH 2 CH 2 CH 3 、OCH(CH 3 ) 2 、
、
Description
Technical Field
The invention relates to an mTOR inhibitor, a preparation method and application, and belongs to the technical field of chemical drugs.
Background
Mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, is widely present in biological cells as two complexes of mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2). mTOR plays an important role in cell growth, apoptosis and autophagy, and is an important component of multiple signal pathways in cells to participate in regulation of organism growth and metabolic balance, so that the mTOR inhibitor is widely applied to the fields of broad-spectrum antibiosis, antivirus, immunosuppression, antitumor and the like.
First generation mTOR inhibitors, such as rapamycin and its derivative analog "rapalogs", are mTORC1 inhibitors that prevent mTOR activation in a conformationally altered manner; for example, everolimus (everolimus) can be combined with an intracellular protein FKBP12 to form an inhibitory complex mTORC1, can inhibit the activity of mTOR, and the inhibition of an mTOR signaling pathway can lead to the reduction of the activities of a transcription regulatory factor S6 ribosomal protein kinase (S6K 1) and a eukaryotic elongation factor 4E-binding protein (4E-BP 1), thereby interfering the translation and synthesis of related proteins such as cell cycle, angiogenesis, glycolysis and the like. However, the compound activates the Akt feedback regulation pathway while inhibiting mTORC1, so that the wide clinical application of the compound is limited, and the drug resistance is generated. Therefore, in order to better meet the requirements of clinical and market, the development of a new mTOR inhibitor which is more effective and has better inhibitory activity has important economic and social benefits.
Disclosure of Invention
In view of the above-mentioned deficiencies of the prior art, the present invention aims to provide an mTOR inhibitor, a preparation method and a use thereof. The mTOR inhibitor provided by the invention is more effective and better in inhibitory activity, is used for preventing and/or treating malignant tumors, immune diseases, viral infection, neurological diseases and the like caused by the dysfunction of an mTOR signaling pathway, and has small side effects. The specific technical scheme is as follows:
in a first aspect, a compound having a structure shown by formula i or a pharmaceutically acceptable salt thereof:
in the formula, R 1 Is selected from
、
、
、
；
R 2 Is selected from C 1 -C 6 Alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
、
、
、
、
、
；
R 3 Selected from H, OH, OCH 3 、OCH 2 CH 3 、OCH 2 CH 2 CH 3 、OCH(CH 3 ) 2 、
、
。
In a second aspect, a method for preparing a compound with a structure shown in formula i or a pharmaceutically acceptable salt thereof comprises the following steps:
in the formula, R 1 、R 2 、R 3 Is as defined for the first aspect R 1 、R 2 、R 3 The definition of (2).
Step 1), synthesis of Compound VII
Carrying out reduction reaction on the compound VIII and a reducing agent in a reaction solvent to obtain a compound VII;
further, in the step 1), the reaction temperature is 20 to 30 ℃, for example, the reaction temperature may be 20 ℃, 25 ℃, 30 ℃ or the like; when the reaction temperature is too low, the reaction rate is slow, and the reaction time is long; when the reaction temperature is too high, the stability of the compound VII (the compound represented by the formula VII) is affected. The reducing agent is at least one of iron powder, zinc powder, palladium carbon, ni and hydrogen, and preferably is the combination of palladium carbon and hydrogen. The reaction solvent is at least one of ethanol, methanol, dioxane and tetrahydrofuran, and preferably methanol.
The yield of the final compound VII can reach 61.2% by means of controlling the reaction temperature, selecting a specific reducing agent and the like.
Step 2) Synthesis of Compound V
Reacting a compound VII and a compound VI in a reaction solvent to obtain a compound V;
further, in the step 2), the reaction temperature is 0-25 ℃; the temperature in the charging stage is controlled to be 0 to 5 ℃, so that the activity of reactants is reduced, and side reactions are inhibited; if the reaction temperature of the main reaction is too low, the reaction rate is slow, and the reaction time is long; therefore, the temperature of the main reaction must be raised, but if the reaction temperature is too high, the side reactions cannot be suppressed, and the final yield is also affected; the optimum reaction temperature for the final main reaction was controlled at 25 ℃. The reaction solvent is at least one of N, N-dimethylformamide and tetrahydrofuran, and tetrahydrofuran is preferred.
By controlling the reaction temperature, the yield of the final compound V can reach 81.1 percent.
Step 3), synthesis of Compound IV
Carrying out reduction reaction on the compound V and a reducing agent in a reaction solvent to obtain a compound IV;
further, in the step 3), the reaction temperature is-30 to 0 ℃; the temperature in the charging stage is controlled to be-30 to-20 ℃, so as to reduce the activity of reactants and inhibit side reactions; however, if the reaction temperature of the main reaction is too low, the reaction rate is slow and the reaction time is long; therefore, the temperature of the main reaction needs to be raised, but if the reaction temperature is too high, side reactions cannot be inhibited, and the final yield is affected; the optimal reaction temperature for the final main reaction was controlled at-10 ℃. The reducing agent is at least one of (+) -diisopinocampheylchloroborane, sodium borohydride and sodium triacetyl borohydride, and the reducing agent is preferably (+) -diisopinocampheylchloroborane. The reaction solvent is at least one of N, N-dimethylformamide, tetrahydrofuran, toluene and N-methylpyrrolidone, and tetrahydrofuran is preferred.
The yield of the final compound IV can reach 71.1 percent by means of controlling the reaction temperature, selecting a specific reducing agent and the like.
Step 4) Synthesis of Compound III
Carrying out hydrolysis reaction on the compound IV and acid in a reaction solvent to obtain a compound III;
further, in the step 4), the reaction temperature is 0 ℃ to 60 ℃, for example, the reaction temperature may be 0 ℃,10 ℃, 20 ℃, 30 ℃, 40 ℃, 50 ℃ or 60 ℃ or the like; the acid is at least one of hydrochloric acid and trifluoroacetic acid, and is preferably trifluoroacetic acid. The reaction solvent is at least one of dichloromethane, methanol and ethanol, and dichloromethane is preferred. The Boc (abbreviation for t-butyloxycarbonyl) on deamination with trifluoroacetic acid is most efficient; in addition, to minimize the degree of racemization, it is desirable to use a lower reaction temperature, e.g., an optimal reaction temperature controlled at 0 ℃.
By means of controlling the reaction temperature, selecting specific acid and the like, the yield of the final compound III can reach 80.1%.
Step 5), synthesis of Compound II-1
Carrying out coupling reaction on a compound II-3, a compound II-2 and alkali in a reaction solvent at the temperature of 40-50 ℃, adding acid after the reaction is finished, and continuing the reaction at the temperature of 10-40 ℃ (carrying out deprotection and ring closure reaction under an acidic condition) to obtain a compound II-1;
further, in the step 5), the base is at least one of triethylamine and diisopropylethylamine, and preferably triethylamine; the acid is at least one of hydrochloric acid and trifluoroacetic acid, and hydrochloric acid is preferred; the reaction solvent is at least one of dichloromethane and N, N-dimethylformamide. In the coupling reaction, the triethylamine is adopted, the reaction efficiency is highest, and the reaction temperature can be 40 ℃, 43 ℃, 46 ℃ or 50 ℃ and the like, preferably 43 +/-3 ℃. The efficiency of performing ring closure reaction by adopting hydrochloric acid is highest; in addition, since a deprotection reaction is involved, a temperature reduction is required, for example, the optimum reaction temperature is controlled to 20. + -. 5 ℃.
By means of controlling the coupling reaction temperature, the deprotection group ring closing reaction temperature, selecting specific acid, alkali and the like, the yield of the compound II-1 can reach 84.0 percent.
Step 6), synthesis of Compound II
Carrying out hydrolysis reaction on the compound II-1 and alkali in a reaction solvent to obtain a compound II;
further, in step 6), the reaction temperature is 20 to 80 ℃, for example, the reaction temperature may be 20 ℃, 25 ℃, 35 ℃, 40 ℃, 45 ℃, 50 ℃, 55 ℃, 60 ℃, 65 ℃, 70 ℃, 75 ℃ or 80 ℃, preferably 25 ℃; the alkali is at least one of sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, potassium tert-butoxide and sodium methoxide, and is preferably sodium hydroxide; the reaction solvent is at least one of tetrahydrofuran, methanol, ethanol and dioxane, and ethanol is preferred.
By means of controlling the reaction temperature, selecting specific alkali and the like, the yield of the compound II can reach 79.3 percent.
Step 7), synthesis of Compound I-1
Reacting the compound II, the compound III, an acid-binding agent and a condensing agent in a reaction solvent to obtain a compound I-1;
further, in the step 7), the reaction temperature is 0-60 ℃; when the compound II, the compound III and the acid-binding agent are added into a reaction solvent, the temperature is reduced to 0 ℃ to inhibit side reaction; however, if the reaction temperature of the main reaction is too low, the reaction rate is slow, and the reaction time is long; therefore, the temperature of the main reaction needs to be raised, but if the reaction temperature is too high, side reactions cannot be inhibited, and the final yield is affected; therefore, after the addition of the condensing agent, the main reaction temperature is raised to 25 ℃. The acid-binding agent is at least one of 4-dimethylamino pyridine and N, N-diisopropylethylamine, and preferably 4-dimethylamino pyridine. The condensing agent is at least one of 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethylurea hexafluorophosphate, O-benzotriazol-tetramethylurea hexafluorophosphate, 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride and N, N '-dicyclohexylcarbodiimide, preferably N, N' -dicyclohexylcarbodiimide. The reaction solvent is at least one of N, N-dimethylformamide, dichloromethane and tetrahydrofuran, and dichloromethane is preferred.
By means of controlling the reaction temperature, selecting specific acid-binding agent, condensing agent and the like, the yield of the compound I-1 can reach 55.6 percent.
Further, when R is 3 Is selected from
The method comprises the following steps:
compound I-1, acetic anhydride (C) 4 H 6 O 3 ) Reacting in a reaction solvent to obtain a compound I-2, wherein the compound I-2 and the compound I are the same compound;
wherein the reaction temperature is 20 to 30 ℃, the reaction temperature is not too high, or by-products are increased, therefore, the reaction temperature is preferably 20 ℃; the reaction solvent is at least one of N, N-dimethylformamide, dichloromethane, tetrahydrofuran and toluene, and toluene is preferred.
By means of controlling the reaction temperature, selecting acetic anhydride as an acylating agent and the like, the yield of the compound I-2 can reach 65.0 percent.
Further, when R is 3 Is selected from
The method comprises the following steps:
reacting a compound I-1, benzyl chloroformate (Cbz-Cl) and alkali in a reaction solvent to obtain a compound I-3, wherein the compound I-3 and the compound I are the same compound;
wherein the reaction temperature is 15-30 ℃, and the alkali is selected from at least one of cesium carbonate, potassium carbonate and sodium bicarbonate, preferably sodium bicarbonate; the reaction solvent is at least one of N, N-dimethylformamide, dichloromethane and tetrahydrofuran, and tetrahydrofuran is preferred.
By means of controlling the reaction temperature, selecting specific alkali and the like, the yield of the compound I-3 can reach 78.3 percent.
Further, when R is 3 When selected from H, the compound I-1 is the same compound as the compound I.
In a third aspect, an mTOR inhibitor, comprising: the compound has a structure shown in formula I or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers or diluents.
In a fourth aspect, the compound with the structure shown in formula I or pharmaceutically acceptable salt thereof is used for preparing a medicament for preventing and/or treating malignant tumor, immune diseases, viral infection and neurological diseases. Wherein the malignant tumor is glioblastoma, renal malignancy, gastric malignancy, malignant skin tumor, rhabdomyosarcoma, bladder malignancy, breast malignancy, uterine malignancy, lung malignancy, colon malignancy, prostate malignancy, ovarian malignancy, or pancreatic malignancy.
The invention has the beneficial effects that:
1) The compound shown in the formula I, the pharmaceutically acceptable salt and the pharmaceutical composition containing the compound as an active ingredient are used as mTOR inhibitors, are more effective and better in inhibitory activity, are used for preventing and/or treating malignant tumors, immune diseases, viral infections, neurological diseases and the like caused by dysfunction of mTOR signaling pathways, and have smaller side effects; therapeutic objectives can be achieved by administering a therapeutically effective dose of one or more compounds of formula I to a patient in need of such prevention and/or treatment.
2) The preparation method is simple, mild in condition, convenient to operate, low in requirement on equipment condition, easy to realize, simple in post-treatment, few in by-products, high in yield, suitable for industrial large-scale production and high in application value.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Definition of
"pharmaceutically acceptable salts" refers to those salts that retain the biological effectiveness and properties of the parent compound. The salt comprises: acid addition salts obtained by reaction of the free base of the parent compound with an inorganic acid or with an organic acid; such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, perchloric acid, and the like; such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, benzenesulfonic acid (benzenesulfonate), benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, gluconic acid, glutamic acid, isethionic acid, lactic acid, maleic acid, mandelic acid, mucic acid, pamoic acid, pantothenic acid, succinic acid, tartaric acid, malonic acid, or the like; preferably hydrochloric acid or (L) -malic acid; or when the acid proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion, an alkaline earth metal ion, or an aluminum ion, or coordinated with an organic base, a salt is formed; such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.
"pharmaceutically acceptable carrier" refers to a pharmaceutical carrier that is conventional in the pharmaceutical art, and that does not significantly stimulate an organism and does not abrogate the biological activity and properties of the administered compound, such as: diluents such as water and the like; fillers, such as starch, sucrose, and the like; binders such as cellulose derivatives, alginates, gelatin, polyvinylpyrrolidone; humectants, such as glycerol; disintegrating agents such as agar, calcium carbonate and sodium bicarbonate; absorption promoters such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and bentonite clay; lubricants, such as talc, calcium stearate and magnesium stearate, and polyethylene glycol, and the like. In addition, other adjuvants such as flavoring agent and sweetener can also be added into the above medicinal composition.
The compounds of the invention may have one or more asymmetric centers; the compounds can thus be prepared as individual (R) -stereoisomers or (S) -stereoisomers or as mixtures thereof. Unless otherwise indicated, the description or designation of a particular compound in the specification and claims is intended to include the individual enantiomers and racemic or other mixtures thereof. Methods for determining stereochemical configuration and separating stereoisomers are well known in the art (see the discussion in chapter 4 of "Advanced Organic Chemistry", 4 th edition, j. March, john Wiley and Sons, new York, 1992). Thus, the present invention also encompasses any stereoisomeric form, its corresponding enantiomers (d-and l-isomers or (+) and (-) isomers), and diastereomers thereof, and mixtures thereof, having mTOR inhibitory activity, and is not limited to any one stereoisomeric form.
"ambient temperature" has the meaning well known in the art and is typically 24 to 28 ℃.
Embodiments of the present invention provide a compound having the structure of formula i or a pharmaceutically acceptable salt thereof:
wherein when R is 3 Selected from H, R 1 Is selected from
、
Or
，R 2 Is selected from
、
、
Or
；
When R is 3 Is selected from
Or
When R is 1 Is selected from
，R 2 Is selected from
。
Further, the structure shown in formula I can be, but is not limited to, the following structure:
the invention is described in detail by taking part of the test results as reference, and the following detailed description is made by combining specific examples.
Example 1
The first step is as follows:
adding a compound VIII (31.3 g,0.1 mol) and palladium carbon (3.1 g) into methanol (300 mL), stirring, introducing hydrogen, keeping the pressure of the hydrogen at 40-50psi, heating to 25 ℃ after stirring, keeping the temperature for reaction for 12 hours, monitoring the reaction by TLC, filtering after the reaction is finished to obtain a first solid, adding the first solid into 500mL of methanol, heating to reflux, carrying out hot filtration to obtain a filtrate, carrying out reduced pressure concentration to obtain a second solid, adding the second solid into a mixed solution of 100mL of ethyl acetate and 100mL of petroleum ether, heating to reflux, cooling and crystallizing to obtain 17.3g of a yellow solid compound VII, wherein the yield is 61.2%. The structural formula of the compound VIII is shown as the formula VIII, and the rest compounds are analogized in the same way.
The second step is that:
dissolving a compound VII (15.0 g, 0.05mol) and a compound VI (di-tert-butyl dicarbonate, 24.1g, 0.11mol) in tetrahydrofuran (400 mL), cooling to 0 to 5 ℃, raising to 25 ℃ after the dissolution is finished, preserving the temperature for 6 hours, monitoring the reaction by TLC, adding water (100 mL) after the reaction is finished, quenching the reaction, separating, taking an organic phase, drying the organic phase with anhydrous sodium sulfate, filtering, concentrating under reduced pressure to obtain 15.5g of oily matter, and purifying to obtain a gray solid compound V with the yield of 81.1%.
The third step:
dissolving a compound V (14.2g, 0.04mol) in tetrahydrofuran (400 mL), cooling to-30 ℃, dropwise adding (+) -diisopinocampheylchloroborane (19.2g, 0.06mol), and keeping the temperature at-20 to-30 ℃ in the dropwise adding process; heating to-10 deg.C, reacting for 16 hr, concentrating under reduced pressure, adding diethyl ether and diethanolamine (77.6 mL, 0.8mol), stirring at room temperature for 4 hr, filtering to obtain organic phase, concentrating, and performing column chromatography (eluent: dichloromethane/methanol = 20/1) to obtain 10.9g oily compound IV with yield of 71.1%.
The fourth step:
dissolving a compound IV (10.0 g, 0.03mol) in dichloromethane (100 mL), cooling to 0 ℃, dropwise adding trifluoroacetic acid (50 mL), heating to room temperature, stirring for reaction for 2 hours, monitoring the reaction by TLC, after the reaction is finished, concentrating under reduced pressure to remove dichloromethane and trifluoroacetic acid, adjusting the pH to 8-10, precipitating a solid, filtering, and drying to obtain 5.9g of a solid compound III, wherein the yield is 80.1%.
The fifth step:
dissolving a compound 1-II-3 (7.0 g, 0.02mol) and a compound 1-II-2 (5.1g, 0.02mol) in dichloromethane (100 mL), slowly adding triethylamine (1.0 g, 0.04mol) dropwise at 40-46 ℃, stirring for reaction for 3 hours, monitoring the reaction by TLC, cooling to 15-25 ℃ after the reaction is finished, adding 32mL of 6N hydrochloric acid aqueous solution dropwise, standing for layering after the reaction is completed, washing an organic phase with a saturated sodium bicarbonate aqueous solution and a saturated sodium chloride aqueous solution, drying the organic phase, and concentrating to obtain 8.2g of solid compound 1-II-1 with the yield of 84.0%.
And a sixth step:
compound 1-II-1 (8.0 g, 0.02mol) was dissolved in ethanol (100 mL), an aqueous sodium hydroxide solution (1.6 g, 0.04mol) was added thereto at room temperature with stirring, the reaction was monitored by TLC, after completion of the reaction, concentration was performed under reduced pressure, a 2N aqueous hydrochloric acid solution was added to adjust the pH to 1 to 2, extraction was performed with ethyl acetate (100 mL. Times.2), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give 5.8g of Compound 1-II as a white solid with a yield of 79.3%.
The seventh step:
mixing the compound 1-II (3.6g,7.9 mmol) is dissolved in dichloromethane (10 mL), compound III (2.3 g,7.9 mmol) and DMAP (4-dimethylaminopyridine, 1.1g,8.7 mmol) are added respectively, the temperature is reduced to 0 ℃, DCC (N, N' -dicyclohexylcarbodiimide, 1.8g,8.7 mmol) is added, the temperature is slowly raised to room temperature, the reaction is continued for 2 hours, the reaction is monitored by TLC, ethyl acetate is added after the reaction is finished, the filtrate is obtained by filtration and is concentrated under reduced pressure to obtain oily matter, 3.2g of compound 1 as white solid is obtained by column chromatography, the yield is 55.6 percent, ESI (+) m/z =728.8 ++ M H] + 。
Example 2
The first step is as follows:
dissolving the compound 2-II-3 (7.4g, 0.02mol) and the compound 1-II-2 (5.1g, 0.02mol) in dichloromethane (100 mL), slowly adding triethylamine (1.0 g, 0.04mol) dropwise at 40-46 ℃, stirring for reaction for 3 hours, monitoring the reaction by TLC, cooling to 15-25 ℃ after the reaction is finished, adding 32mL of 6N hydrochloric acid aqueous solution dropwise, standing for layering after the reaction is finished, washing an organic phase with a saturated sodium bicarbonate aqueous solution and a saturated sodium chloride aqueous solution, drying the organic phase, and concentrating to obtain 8.2g of solid compound 2-II-1 with the yield of 82.1%.
The second step is that:
compound 2-II-1 (8.0 g,15.6 mmol) was dissolved in ethanol (100 mL), aqueous sodium hydroxide (1.3 g, 31.8mmol) was added thereto at room temperature with stirring, the reaction was monitored by TLC, after completion of the reaction, concentration was carried out under reduced pressure, 2N aqueous hydrochloric acid was added to adjust the pH to 1 to 2, extraction was carried out with ethyl acetate (100 mL. Times.2), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give 5.6g of Compound 2-II as a white solid in a yield of 76.1%.
The third step:
dissolving compounds 2-II (3.8g, 8.0mmol) in dichloromethane (20 mL), adding compound III (2.4g, 8.0mmol) and DMAP (4-dimethylaminopyridine, 1.2g, 8.0mmol) respectively, cooling to 0 ℃, adding DCC (N, N' -dicyclohexylcarbodiimide, 1.8g, 8.8mmol), slowly raising to room temperature, continuing to react for 2 hours, monitoring the reaction by TLC, adding ethyl acetate after the reaction is finished, filtering to obtain a filtrate, concentrating the filtrate under reduced pressure to obtain an oily substance, and performing column chromatography to obtain 2.7g of compound 2 as a white solid, wherein the yield is 45.1%, and ESI (+) m/z = 742.8M H + C] + 。
Example 3
The first step is as follows:
dissolving the compound 3-II-3 (0.7g, 1.89mmol) and the compound 1-II-2 (0.5g, 1.89mmol) in dichloromethane (10 mL), slowly dropwise adding triethylamine (0.4g, 3.8mol) at 40 to 46 ℃, stirring for reaction for 3 hours, monitoring the reaction by TLC, after the reaction is finished, cooling to 15 to 25 ℃, dropwise adding 5mL 6N hydrochloric acid aqueous solution, standing for layering after the reaction is finished, washing an organic phase by using saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution, drying the organic phase, and concentrating to obtain 0.8g of solid compound 3-II-1 with the yield of 84%.
The second step is that:
compound 3-II-1 (0.5g, 1mmol) was dissolved in ethanol (10 mL), an aqueous sodium hydroxide solution (0.12g, 3mmol) was added with stirring at room temperature, the reaction was monitored by TLC, after completion of the reaction, concentration was performed under reduced pressure, a 2N aqueous hydrochloric acid solution was added to adjust the pH to 1 to 2, extraction was performed with ethyl acetate (50 mL. Times.2), the organic layers were combined, dried over anhydrous sodium sulfate, and concentration was performed to obtain 0.34g of compound 3-II as an off-white solid in a yield of 72.1%.
The third step:
dissolving compound 3-II (0.3g, 0.6 mmol) in dichloromethane (5 mL), adding compound III (0.17g, 0.6 mmol) and DMAP (4-dimethylaminopyridine, 0.1g,0.7 mmol) respectively, cooling to 0 deg.C, adding DCC (N, N' -dicyclohexylcarbodiimide, 0.14g,0.7 mmol), slowly raising to room temperature, continuing the reaction for 2 hours, monitoring the reaction by TLC, after the reaction is finished, adding ethyl acetate, filtering to obtain filtrate, concentrating the filtrate under reduced pressure to obtain oily substance, and performing column chromatography to obtain 0.18g of compound 3 as white solid with yield of 41.1%, ESI (+) m/z =742.8[ M + ] H ]] + 。
Example 4
The first step is as follows:
dissolving the compound 4-II-3 (1.0g, 2.8mmol) and the compound 1-II-2 (0.7g, 2.8mmol) in dichloromethane (5 mL), slowly dropwise adding triethylamine (0.6 g,5.6 mol) at 40-46 ℃, stirring for reaction for 3 hours, monitoring the reaction by TLC, after the reaction is finished, cooling to 15-25 ℃, dropwise adding 4mL, 6N hydrochloric acid aqueous solution, standing for layering after the reaction is finished, washing an organic phase by using saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution, drying the organic phase, and concentrating to obtain 1.1g of solid compound 4-II-1, wherein the yield is 80%.
The second step:
compound 4-II-1 (0.7g, 1.4mmol) was dissolved in ethanol (5 mL), aqueous sodium hydroxide (0.17g, 4.2mmol) was added with stirring at room temperature, the reaction was monitored by TLC, after completion of the reaction, concentration was performed under reduced pressure, 2N aqueous hydrochloric acid was added to adjust pH to 1 to 2, extraction was performed with ethyl acetate (50 mL × 2), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain 0.45g of compound 4-II as a white solid in a yield of 70%.
The third step:
dissolving compound 4-II (0.4 g,0.9 mmol) in dichloromethane (5 mL), adding compound III (0.26g, 0.9 mmol) and DMAP (4-dimethylaminopyridine, 0.12g, 1mmol) respectively, cooling to 0 ℃, adding DCC (N, N' -dicyclohexylcarbodiimide, 0.2g, 1mmol), slowly raising to room temperature, continuing to react for 2 hours, monitoring the reaction by TLC, after the reaction is completed, adding ethyl acetate, filtering to obtain filtrate, concentrating the filtrate under reduced pressure, and performing column chromatography to obtain 0.3g of compound 4 as solid, wherein the yield is 44.1%, and ESI (+) m/z =730.4[ [ M ] H + H ], [ 1 ]] + 。
Example 5
Compound 1 (0.3g, 0.4mmol) was dissolved in toluene (4 mL), warmed to 50 ℃ and stirred to dissolve, then cooled to 20 ℃ and acetic anhydride (C) was added dropwise 4 H 6 O 3 81.6mg,0.8 mmol), keeping the temperature for continuous reaction after finishing the dropwise addition, monitoring the reaction by TLC, adding an aqueous solution of sodium bicarbonate after the reaction is finished, stirring for 30 minutes, adding ethyl acetate, stirring for layering, and concentrating the organic phase under reduced pressure to obtain 0.2g of oily compound 5, wherein the yield is 65.0 percent, and ESI (+) m/z =770.8[ M ] +H ]] + 。
Example 6
Compound 1 (0.3g, 0.4mmol) was dissolved in tetrahydrofuran (4 mL), and sodium hydrogencarbonate (67.2mg, 0.8mmol) and Cbz-Cl (benzyl chloroformate, 107.4mg, 0.6mmol) were added, followed by addition at room temperatureContinuing the reaction, monitoring the reaction by TLC, after the reaction is completed, adding water, stirring for 30 min, adding ethyl acetate, stirring for layering, drying the organic phase with anhydrous sodium sulfate, and concentrating under reduced pressure to obtain 0.27g of compound 6 as oil with yield of 78.3%, ESI (+) m/z =862.9[ M + ] H +] + 。
Example 7
The first step is as follows:
dissolving the compound 7-II-3 (1.0g, 2.8mmol) and the compound 7-II-2 (730.8mg, 2.8mmol) in dichloromethane (5 mL), slowly dropwise adding triethylamine (0.6 g,5.6 mol) at 40-46 ℃, stirring for reaction for 3 hours, monitoring the reaction by TLC, after the reaction is finished, cooling to 15-25 ℃, dropwise adding 4mL, 6N hydrochloric acid aqueous solution, standing for layering after the reaction is finished, washing an organic phase with a saturated sodium bicarbonate aqueous solution and a saturated sodium chloride aqueous solution, drying the organic phase, and concentrating to obtain 1.1g of the solid compound 7-II-1, wherein the yield is 78%.
The second step:
compound 7-II-1 (0.7 g,1.4 mmol) was dissolved in ethanol (10 mL), an aqueous sodium hydroxide solution (0.17g, 4.2mmol) was added under stirring at room temperature, the reaction was monitored by TLC, after completion of the reaction, concentration was performed under reduced pressure, 2N aqueous hydrochloric acid was added to adjust pH to 1 to 2, extraction was performed with ethyl acetate (50 mL × 2), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain 0.46g of compound 7-II as a white-like solid in a yield of 70%.
The third step:
compound 7-II (0.4g, 0.9mmol) was dissolved in dichloromethane (5 mL), and Compound III (0.26g, 0.9mmol) was addedAnd DMAP (4-dimethylaminopyridine, 0.12g, 1mmol), cooling to 0 ℃, adding DCC (N, N' -dicyclohexylcarbodiimide, 0.2g, 1mmol), slowly raising to room temperature, continuing to react for 2 hours, monitoring the reaction by TLC, after the reaction is finished, adding ethyl acetate, filtering to obtain a filtrate, concentrating the filtrate under reduced pressure to obtain an oily substance, and performing column chromatography to obtain 0.3g of solid compound 7, wherein the yield is 44.0%, ESI (+) m/z = 733.2M + H] + 。
Example 8
The structural formula of compound 8 is shown in formula 8, which is a white solid, ESI (+) m/z =716.8[ 2 ] M + H] + 。
Biological evaluation test
U87MG Human Glioblastoma(ATCC)
3 H Thymidine Incorporation Protocol
Growth medium: BRL essential Medium (500 mL) containing Earle Salts
+5mL BRL MEN non-essential amino acid (10 mM)
+5mL BRL penicillin and streptomycin (10000 microgram/mL )
+5mL BRL sodium pyruvate solution (100 mM)
+5mL BRL-glutamate (200 mM)
+50mL fetal bovine serum
The test procedure was as follows:
1. cells were trypsinized at a final volume of 10 in 200. Mu.l growth medium 4 The concentration of cells/well was placed in a 96-well flat bottom plate and adhered at 37 ℃ for 24 hours.
2. The medium was carefully removed with a pipette so as not to disturb the cell monolayer, 200. Mu.l of fresh growth medium was added to each well, 10. Mu.l of each of compounds 1 to 8 was added, and the mixture was further cultured at 37 ℃ for 48 hours.
3. At the end of the 5 hours of incubation, the plates were plated with 1. Mu. Ci 3 H-thymidine is used for calibration. AddingAdd 10. Mu.l of 11. Mu. Ci of Compounds 1 to 8 and place the plate back in the incubator for the last 5 hours.
4. The radioactive medium was carefully removed with a pipette so as not to disturb the cell monolayer. Add 50. Mu.l BRL 10 Xtrypsin to each well, followed by incubation at 37 ℃ for 10 minutes or until the monolayer is shed from the bottom well. Samples were harvested on glass fiber filter pads using a Skatron 96-well harvester and counted on a Wallac Betaplate counter. Calculating to obtain IC of the target compound 50 The values are shown in Table 1:
TABLE 1
As shown in Table 1, the compounds 1 to 8 have good inhibitory effect on mTOR, wherein the inhibitory activity of the compounds 1 and 6 is the highest.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (10)
1. A compound having the structure shown in formula I or a pharmaceutically acceptable salt thereof:
in the formula, R 1 Is selected from
、
、
、
；
R 2 Is selected from
、
、
、
；
R 3 Selected from H, OH, OCH 3 、OCH 2 CH 3 、OCH 2 CH 2 CH 3 、OCH(CH 3 ) 2 、
、
。
2. The compound or pharmaceutically acceptable salt thereof according to claim 1,
when R is 3 Selected from H, R 1 Is selected from
、
Or
，R 2 Is selected from
、
、
Or
；
When R is 3 Is selected from
Or
When R is 1 Is selected from
，R 2 Is selected from
。
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from any one of the following formulas 1-8, and has the following structural formula:
4. a process for the preparation of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, comprising the steps of:
in the formula, R 1 、R 2 、R 3 As defined in any one of claims 1 to 3 for R 1 、R 2 、R 3 The definition of (1);
step 1) Synthesis of Compound VII
Reacting the compound VIII with a reducing agent in a reaction solvent to obtain a compound VII;
step 2), synthesis of Compound V
Reacting a compound VII and a compound VI in a reaction solvent to obtain a compound V;
step 3), synthesis of Compound IV
Reacting the compound V and a reducing agent in a reaction solvent to obtain a compound IV;
step 4), synthesis of Compound III
Reacting the compound IV with acid in a reaction solvent to obtain a compound III;
step 5), synthesis of Compound II-1
Reacting the compound II-3, the compound II-2 and alkali in a reaction solvent, and adding acid to continue reacting after the reaction is finished to obtain a compound II-1;
step 6), synthesis of Compound II
Reacting the compound II-1 with alkali in a reaction solvent to obtain a compound II;
step 7), synthesis of Compound I-1
Reacting the compound II, the compound III, an acid-binding agent and a condensing agent in a reaction solvent to obtain a compound I-1;
when R is 3 Is selected from
When the temperature of the water is higher than the set temperature,
reacting the compound I-1 and acetic anhydride in a reaction solvent to obtain a compound I-2, wherein the compound I-2 and the compound I are the same compound;
when R is 3 Is selected from
When the temperature of the water is higher than the set temperature,
reacting the compound I-1, benzyl chloroformate and alkali in a reaction solvent to obtain a compound I-3, wherein the compound I-3 and the compound I are the same compound;
when R is 3 When selected from H, compound I-1 is the same compound as Compound I.
5. The preparation method of claim 4, wherein in the step 1), the reaction temperature is 20-30 ℃, the reducing agent is at least one of iron powder, zinc powder, palladium carbon, ni and hydrogen, and the reaction solvent is at least one of ethanol, methanol, dioxane and tetrahydrofuran;
in the step 2), the reaction temperature is 0-25 ℃, and the reaction solvent is at least one of N, N-dimethylformamide and tetrahydrofuran;
in the step 3), the reaction temperature is-30-0 ℃, the reducing agent is at least one of (+) -diisopinocampheylchloroborane, sodium borohydride and sodium triacetyl borohydride, and the reaction solvent is at least one of N, N-dimethylformamide, tetrahydrofuran, toluene and N-methylpyrrolidone;
in the step 4), the reaction temperature is 0-60 ℃, the acid is at least one of hydrochloric acid and trifluoroacetic acid, and the reaction solvent is at least one of dichloromethane, methanol and ethanol;
in the step 5), reacting a compound II-3, a compound II-2 and alkali in a reaction solvent at the temperature of 40-50 ℃, adding acid, and continuing to react at the temperature of 10-40 ℃, wherein the alkali is at least one of triethylamine and diisopropylethylamine, the acid is at least one of hydrochloric acid and trifluoroacetic acid, and the reaction solvent is at least one of dichloromethane and N, N-dimethylformamide;
in the step 6), the reaction temperature is 20-80 ℃, the alkali is at least one of sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, potassium tert-butoxide and sodium methoxide, and the reaction solvent is at least one of tetrahydrofuran, methanol, ethanol and dioxane;
in the step 7), the reaction temperature is 0-60 ℃, the acid-binding agent is at least one of 4-dimethylaminopyridine and N, N-diisopropylethylamine, the condensing agent is at least one of 2- (7-azobenzotriazol) -N, N, N ', N ' -tetramethylurea hexafluorophosphate, O-benzotriazol-tetramethylurea hexafluorophosphate, 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride and N, N ' -dicyclohexylcarbodiimide, and the reaction solvent is at least one of N, N-dimethylformamide, dichloromethane and tetrahydrofuran.
6. The method of claim 5, wherein when R is 3 Is selected from
In the preparation method, the compound I-1 and acetic anhydride react in a reaction solvent at a temperature of 20 to 30 ℃, wherein the reaction solvent is at least one of N, N-dimethylformamide, dichloromethane, tetrahydrofuran and toluene.
7. The method according to claim 5, wherein when R is 3 Is selected from
In the method, the compound I-1, benzyl chloroformate and alkali react in a reaction solvent at the temperature of 15-30 ℃, wherein the alkali is at least one of cesium carbonate, potassium carbonate and sodium bicarbonate, and the reaction solvent is at least one of N, N-dimethylformamide, dichloromethane and tetrahydrofuran.
8. An mTOR inhibitor, comprising: a compound as claimed in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or diluents.
9. Use of the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in preparation of a medicament for preventing and/or treating malignant tumors, immune diseases, viral infections and neurological diseases.
10. Use of a compound according to claim 9 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention and/or treatment of a malignancy, an immunological disorder, a viral infection, a neurological disorder, wherein the malignancy is glioblastoma, renal malignancy, gastric malignancy, malignant skin neoplasm, rhabdomyosarcoma, bladder malignancy, breast malignancy, uterine malignancy, lung malignancy, colon malignancy, prostate malignancy, ovarian malignancy, or pancreatic malignancy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211194474.5A CN115304600B (en) | 2022-09-29 | 2022-09-29 | mTOR inhibitor, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211194474.5A CN115304600B (en) | 2022-09-29 | 2022-09-29 | mTOR inhibitor, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115304600A CN115304600A (en) | 2022-11-08 |
| CN115304600B true CN115304600B (en) | 2023-01-13 |
Family
ID=83865939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211194474.5A Active CN115304600B (en) | 2022-09-29 | 2022-09-29 | mTOR inhibitor, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115304600B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115487186B (en) * | 2022-09-29 | 2024-04-16 | 北京朗瑞邦科技有限公司 | Pharmaceutical preparation with mTOR inhibition activity and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006090169A1 (en) * | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
| CN101128204A (en) * | 2005-02-25 | 2008-02-20 | 库多斯药物有限公司 | 2,4-diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors |
| CN101675051A (en) * | 2007-03-21 | 2010-03-17 | 惠氏公司 | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| CN103596953A (en) * | 2011-06-04 | 2014-02-19 | 山东轩竹医药科技有限公司 | Pyridonaphthyridine PI3K/mTOR dual inhibitors and preparation and use thereof |
| CN104768952A (en) * | 2012-08-08 | 2015-07-08 | 山东亨利医药科技有限责任公司 | PI3Kdelta inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10348022A1 (en) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
| JP5878628B2 (en) * | 2011-06-04 | 2016-03-08 | シュアンジュ・ファーマ・カンパニー・リミテッド | Pyridonaphthyridine-type PI3K and mTOR dual inhibitors and their preparation and use |
| ES2627099T3 (en) * | 2012-08-06 | 2017-07-26 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of diseases related to the mTOR pathway |
-
2022
- 2022-09-29 CN CN202211194474.5A patent/CN115304600B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006090169A1 (en) * | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
| CN101128204A (en) * | 2005-02-25 | 2008-02-20 | 库多斯药物有限公司 | 2,4-diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors |
| CN101675051A (en) * | 2007-03-21 | 2010-03-17 | 惠氏公司 | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| CN103596953A (en) * | 2011-06-04 | 2014-02-19 | 山东轩竹医药科技有限公司 | Pyridonaphthyridine PI3K/mTOR dual inhibitors and preparation and use thereof |
| CN104768952A (en) * | 2012-08-08 | 2015-07-08 | 山东亨利医药科技有限责任公司 | PI3Kdelta inhibitor |
Non-Patent Citations (2)
| Title |
|---|
| mTOR抑制剂的研究概况;唐琰等;《有机化学》;20110715;第31卷(第07期);第1144-1154页 * |
| PI3K-Akt-mTOR通路及其小分子抑制剂的研究进展;何俏军等;《中国生化药物杂志》;20160828;第36卷(第08期);第6-15页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115304600A (en) | 2022-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6805220B2 (en) | Therapeutically active compounds and how to use them | |
| CA3213029A1 (en) | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof | |
| TW200932214A (en) | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide | |
| JP2016169161A (en) | Novel imidazo pyridine compound | |
| US9890181B2 (en) | Silicon phthalocyanine complex, preparation method and medicinal application thereof | |
| RU2730500C2 (en) | Quinazolinone derivative, a method for production thereof, a pharmaceutical composition and use thereof | |
| CN115304600B (en) | mTOR inhibitor, preparation method and application | |
| JP2002509930A (en) | Benzoheterocyclic distamycin derivatives, process for their preparation and their use as antitumor agents | |
| EP4137480A1 (en) | Amino acid derivative containing non-steroidal anti-inflammatory drug structure, preparation method therefor and application thereof | |
| WO2016117647A1 (en) | New benzimidazole derivative and pharmaceutical use thereof | |
| US20220370429A1 (en) | Aromatic heterocyclic compound having tricyclic structure, and preparation method therefor and application thereof | |
| CN108947912B (en) | Neddylation pathway targeted anti-tumor compound | |
| CN111116469A (en) | HDAC inhibitor, preparation method, pharmaceutical composition and application thereof | |
| CN115135646B (en) | Substituted polycyclic compounds, pharmaceutical compositions and uses thereof | |
| MX2008013435A (en) | Synthesis and uses of pyroglutamic acid derivatives. | |
| JP2023511222A (en) | Substituted pyridazinone compounds and uses thereof | |
| EP0620224B1 (en) | Triazolopyridazine derivatives, their production and use | |
| WO2015113521A1 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
| CN112225742B (en) | Compound for inhibiting VEGFR activity, preparation method and application | |
| AU2018236530B2 (en) | Deuterated benzimidazole compound and medicinal use thereof | |
| CN109748914B (en) | Pyridopyrimidine compound and application thereof | |
| US11440916B2 (en) | Selective A2A receptor antagonist | |
| JP2002517494A (en) | Cinnamoyldistamycin analog derivative, process for its production and use as antitumor agent | |
| US20230278993A1 (en) | Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof | |
| CN113816965B (en) | Compound with IDO (indomethacin diphosphate) inhibitory activity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: MTOR inhibitors, preparation methods, and applications Effective date of registration: 20230829 Granted publication date: 20230113 Pledgee: Industrial Bank Co.,Ltd. Beijing Pinggu Branch Pledgor: BEIJING XINKAIYUAN PHARMACEUTICAL TECHNOLOGY CO.,LTD. Registration number: Y2023110000364 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20240730 Granted publication date: 20230113 |